Effects of montelukast and salmenterol on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction

Chest

Volumn 126, Issue 4, 2004, Pages 1154-1160

  Steinshamn, Sigurd ^a   Sandsund, Mariann ^b   Sue Chu, Malcolm ^a   Bjermer, Leif ^a  

^a TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^b SINTEF   (Norway)

Author keywords

Asthma; Exercise economy; Exercise induced bronchoconstriction; Gas exchange; Lung function; Montelukast; Physical performance; Salmeterol

Indexed keywords

MONTELUKAST; SALMETEROL; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; DRUG DERIVATIVE; LACTIC ACID DERIVATIVE; QUINOLINE DERIVATIVE; SALBUTAMOL;

ADULT; ARTICLE; ASTHMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; EXERCISE; FEMALE; HEART RATE; HUMAN; LUNG FUNCTION; LUNG GAS EXCHANGE; LUNG VENTILATION; MALE; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; RUNNING; ADOLESCENT; BRONCHOSPASM; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; EXERCISE INDUCED ASTHMA; FORCED EXPIRATORY VOLUME; PATHOPHYSIOLOGY;

ACETATES; ADOLESCENT; ADRENERGIC BETA-AGONISTS; ADULT; ALBUTEROL; ANTI-ASTHMATIC AGENTS; ASTHMA, EXERCISE-INDUCED; BRONCHOCONSTRICTION; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LACTATES; MALE; PULMONARY GAS EXCHANGE; QUINOLINES;

EID: 6344280295     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.126.4.1154     Document Type: Article

References (28)

1. Robuschi M, Riva E, Fuccella LM, et al. Prevention of exercise-induced bronchoconstriction by a new leukotriene antagonist: a double-blind study versus disodium cromoglycate and placebo. Am Rev Respir Dis 1992; 145:1285-1288
2. Leff JA, Busse WW, Pearlman D, et al, Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998; 339:147-152
3. Kemp JP, Dockhorn RJ, Busse WW, et al. Prolonged effect of inhaled salmeterol against exercise-induced bronchospasm. Am J Respir Crit Care Med 1994; 150:1612-1615
4. DaCosta J, Hedstrand U. The effect of a new sympathomimethic beta-receptor stimulating drug (terbutaline) on arterial blood gases in bronchial asthma. Scand J Respir Dis 1970; 51:212-217
5. Ringsted CV, Eliasen K, Andersen JB, et al. Ventilation-perfusion distributions and central hemodynamics in chronic obstructive pulmonary disease: effects of terbutaline administration. Chest 1989; 96:976-983
6. Holmgren D, Sixt R. Effects of salbutamol inhalations on transcutaneous blood gases in children during the acute asthmatic attack: from acute deterioration to recovery. Acta Paediatr 1994; 83:515-519
7. Revill SM, Morgan MD. The cardiorespiratory response to submaximal exercise in subjects with asthma following pretreatment with controlled release oral salbutamol and high-dose inhaled salmeterol. Respir Med 1998; 92:1053-1058
8. 4-receptor antagonism in the airways of patients with asthma. Clin Pharmacol Ther 1997; 61:83-92
9. 4 receptor antagonist. Can J Physiol Pharmacol 1995; 73:191-201
10. Steinshamn S, Sandsund M, Sue-Chu M, et al. Effects of montelukast on physical performance and exercise economy in adult asthmatics with exercise-induced bronchoconstriction. Scand J Med Sci Sports 2002; 12:211-217
11. Anderson SD, Silverman M, Tai E, et al. Specificity of exercise in exercise-induced asthma. BMJ 1971; 4:814-815
12. Jones NL, ed. Clinical exercise testing, 4th ed. Philadelphia, PA: W.B. Saunders Company, 1997; 53
13. Jones NL. Clinical exercise testing, 4th ed. Philadelphia, PA: W.B. Saunders Company, 1997; 135
14. Roca J, Whipp BJ, Agusti AGN, et al. Clinical exercise testing with reference to lung diseases: indications, standardisations and interpretation strategies. Eur Respir J 1997; 10:2662-2689
15. Bjermer L. History and future perspectives of treating asthma as a systemic and small airways disease. Respir Med 2001; 95:703-719
16. Laurent F, Latrabe V, Raherison C, et al. Functional significance of air trapping detected in moderate asthma. Eur Radiol 2000; 10:1404-1410
17. Hui KP, Barnes NC. Lung function improvement in asthma with a cysteinyl-leukotriene receptor antagonist. Lancet 1991; 337:1062-1063
18. Sue-Chu M, Sandsund M, Helgerud J, et al. Salmeterol and physical performance at - 15°C in highly trained nonasthmatic cross-country skiers. Scand J Med Sci Sports 1999; 9:48-52
19. Sue-Chu M, Sandsund M, Holand B, et al. Montelukast does not affect exercise performance and subfreezing temperature in highly trained non-asthmatic endurance athletes. Int J Sports Med 2000; 21:424-428
20. 4 in rat heart. Am J Physiol 1990; 259:H1239-H1246
21. Graff-Lonnevig V, Bevergaard S, Eriksson BO. Ventilation and pulmonary gas exchange at rest and during exercise in boys with bronchial asthma. Eur J Respir Dis 1980; 61:357-366
22. Munkner T, Bundgaard A. Regional V/Q changes in asthmatics after exercise. Eur J Respir Dis Suppl 1986; 143:62-66
23. Young IH, Corte P, Schoeffel RE. Pattern and time course of ventilation-perfusion inequality in exercise-induced asthma. Am Rev Respir Dis 1982; 125:304-311
24. Villaran C, O'Neill SJ, Helbling A, et al. Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group. J Allergy Clin Immunol 1999; 104:547-553
25. Edelman JM, Turpin JA, Bronsky EA, et al. Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction: a randomized, double-blind trial. Exercise Study Group. Ann Intern Med 2000; 132:97-104
26. Bhagat R, Kalra S, Swystun VA, et al. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108:1235-1239
27. Currie GP, Lee DK, Haggart K, et al. Effects of montelukast on surrogate inflammatory markers in corticosteroid treated asthmatics. Am J Respir Crit Care Med 2003; 167:1232-1238
28. Storms WW, Bird S, Firriolo KM, et al. The effect of rescue short-acting beta-agonist bronchodilation in patients on montelukast or salmeterol [abstract]. J Allergy Clin Immunol 2003; 107(suppl):316